Bangkok Tenofovir Study (BTS) Follow-Up

Phase:Open Label
Principal Investigator(s):
Objective:Follow-on trial of daily oral TDF in men and women who inject drugs. *Preliminary data reported in February 2015 showed that 35% of eligible participants decided to participate in the OLE, with a limited number of participants returning to the clinic suggesting the need for adherence support.*
Prevention Option(s):PrEP
Study Design:Open label
Trial Sponsors: Bangkok Metropolitan Administration, CDC, Gilead
Start Date
End Date
Age range: ↔ any
Population:Cisgender Men, Cisgender Women, Injecting drug users